Bayer and Onyx' Nexavar Approved in Europe
Posted on: Monday, 24 July 2006, 12:00 CDT
The European Commission has granted marketing authorization to Bayer and Onyx' Nexavar tablets for the treatment of patients with advanced kidney cancer who have failed prior therapy.
The Nexavar approval is specifically for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon- alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Nexavar will be commercialized in Europe by Bayer.
The European approval was based on phase III data from the largest randomized, placebo-controlled trial ever conducted in patients with advanced renal cell carcinoma. In the study, Nexavar doubled progression- free survival in previously treated patients when compared to placebo.
"For more than a decade, Europeans with kidney cancer have not had a new approved treatment. We are pleased to play a part in addressing this unmet medical need," said Dr Gunnar Riemann, head of Bayer HealthCare's pharmaceuticals division.
Nexavar was approved by the FDA in December 2005 and has since been approved in Switzerland, Mexico, Chile, Brazil, Korea, and Argentina. Regulatory filings have been completed in several countries, including Australia, Canada, Turkey, and Japan.
Source: Datamonitor
Related Articles
- Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
- Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
- New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
- RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- North Shore Radiation Therapy Opens on Long Island, Offers Cancer Patients Access to New, Advanced Cancer Treatments
- Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) As First-Line Therapy for Patients With Advanced Melanoma
- Published Clinical Study Shows Zynex's NeuroMove Stroke Recovery Systems As Enabling Patients to Advance to Physical Therapy
- New Treatment Extends Survival for Patients with Advanced Lung Cancer
- OvaRex MAb for Patients With Advanced Ovarian Cancer May Extend Remission Following Favorable Surgery and Chemotherapy
- Richland Firm IsoRay Introduces Promising Cancer Treatment Therapy
 |
 |
User Comments (0)
RSS Feeds